Comment: New PD-1 checkpoint inhibitors for treating Hodgkin lymphoma

Visit http://www.ecancer.org for more.

Dr Bollard talks to ecancertv at ASH 2014 about key abstracts highlighted by the conference and their implications for the field.

She comments first on the use of checkpoint inhibitors to manipulate the PD-1 pathway, touching first on Professor Armand's work with nivolumab and then Professor Moskowitz's study on pembrolizumab, both of which addressed Hodgkin lymphoma.

Dr Bollard is also a member of the Division of the Blood and Marrow Transplantation and senior scientist at the Children National Health System's Center for Cancer and Immunology Research at Children’s Research Institute. She is the Principal Investigator and the Sheikh Zayed Institute for Pediatric Surgical Innovation.